Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5123257 | 1.00 | AR (0.42) | ARMEN1CYP1A2POLBCYP2D6 | |
| SCHEMBL5122002 | 0.88 | AR (0.55) | ARCDK1 | |
| SCHEMBL5124748 | 0.88 | AR (0.55) | ARCDK1 | |
| SCHEMBL5116557 | 0.87 | AR (0.45) | AR | |
| SCHEMBL5123270 | 0.86 | AR (0.56) | AR | |
| SCHEMBL5115984 | 0.84 | AR (0.55) | ARTRPA1HCRTR1HCRTR2CDK1 | |
| SCHEMBL5486825 | 0.84 | AR (0.55) | ARTRPA1HCRTR1HCRTR2CDK1 | |
| SCHEMBL5114835 | 0.83 | AR (0.53) | ARTRPA1CDK1 | |
| SCHEMBL5114827 | 0.83 | AR (0.53) | ARTRPA1CDK1 | |
| SCHEMBL5118678 | 0.82 | AR (0.40) | ARTRPA1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | HIGUCHI ROBERT I | 2008-12-04 | — | — | US | disclosed |
| US-7214690-B2 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2007-03-29 | — | — | US | disclosed |
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885MEN1 2192/4885CYP1A2 181/4885 |
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885MEN1 2402/4885CYP1A2 163/4885 |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885MEN1 2402/4885CYP1A2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.